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Neurological Adverse Events to Voriconazole: 
Evidence for Therapeutic Drug Monitoring 
A. Imhof*, D.J. Schaer, M. Schneemann, 
R. Laffer, U. Schanz. Department of Internal 
Medicine University Hospital ZUrich, 8091 ZUrich, 
Switzerland 
Background: Treatment with voriconazoLe (VOR), a 
broad-spectrum second-generation azoLe antifun- 
gaL agent, has been shown to result in favorable 
outcomes in the setting of muLtipLe opportunistic 
fungaL infections. VOR has a considerable interpa- 
tient variation of serum concentrations, and recent 
observations suggest hat adverse vents might be 
close related. 
Objectives: Association of VOR serum Level in- 
crease (sVL) with severe neuroLogicaL adverse 
eve n ts. 
Methods E Results: In a retrospective analysis 
of 28 treatment courses, 6 patients presented 
with neuroLogicaL adverse events (nAE, haLLuci- 
nation, encephaLopathy, and visual disturbance). 
OR per 0.1 pg/mL sVL was 2.34, (95% CI: 1.54-3.55, 
p<0.001). The ROC curve for nAE for each of 
the sVL cut points shows a very good accuracy 
(area under the ROC curve = 0.846). ALL nAE 
occurred within 3 to 22 days (median: 7 days) 
after start of VOR treatment or dosage adjust- 
ment. Longer duration of VOR treatment was sig- 
nificantLy associated with Less nAE (OR per 10 
days of VOR treatment: 0.87, 95%CI: 0.78-0.96, 
p= 0.008). There was no correlation between sVL 
and creatinine (r=0.12, p=0.114), ALT (r=-0.14, 
p = 0.072), AST (r = 0.003, p = 0.964), aLkaLine phos- 
phatase (r=0.03, p=0.723). 
Conclusions: Our findings demonstrate that the 
potential for emergence of neuroLogicaL adverse 
events is associated with elevated sVL and mea- 
surement of serum concentration could improve 
voMconazoLe treatment and safety. 
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Combined Galactomannan (GMn), Mannan (Mn), 
and Anti-Mannan (AMn) for Diagnosis of Invasive 
Fungal Infections (IFI) in Neutropenic Cancer 
Patients (Pts) 
L. Senn*, J.O. Robinson, S. Schmidt, M. Knaup, 
B. Duvoisin, J. BiLLe, T. CaLandra, O. Marchetti. 
Infectious Diseases Service, EHUV, Lausanne, 
Switzerland 
Background: Invasive aspergiLLosis (IA) and can- 
didiasis (IC) are Life-threatening complications in 
neutropenic cancer pts. Diagnosis remains difficult 
and is often delayed when relying on conventional 
methods. Thus, empirical antifungaL Rx is a stan- 
dard of care in neutropenic patients with persistent 
fever. Detection of fungaL antigens and antibodies 
may help to guide antifungaL Rx. 
Objectives: to evaluate the utility of a combined 
monitoring of GMn, Mn and AMn in neutropenic 
cancer patients. 
Methods: Prospective evaluation of consecutive 
episodes of neutropenia (median duration 22 d) in 
pts with acute Leukemia. IFI was diagnosed accord- 
ing to EORTC-MSG criteria. BLood was coLLected 
2 times weekly before onset of fever and daily 
thereafter. GMn, Mn and AMn were measured by 
ELISA (PLateLia, Bio-Rad). Positive tests were de- 
fined by 2 consecutive values of GMn 70.3, 0.4, 0.5 
or >I.0OD Index, of Mn >0.25 or 0.5 ng/mL and of 
AMn >5 or 10AU/mL. 
Results: 14 IA (5 proven, 9 probable) and 13 IC 
(1 proven, 12 probable) occurred in 154 neu- 
tropenic episodes. 16 samples per episode (5-47) 
were analyzed over 35d (17-122). Diagnostic per- 
formance of GMn in IA and Mn/AMn in IC: the 
sensitivity of Lower cut-offs was higher than that 
of the recommended cut-offs, the specificity was 
similar. Diagnostic performance of the combined 
markers: the NPV was high and the LikeLihood ratio 
of a negative test was 0.05. In 87% of Pts with 
IFI, positive tests preceded cLinicaL diagnosis by 
a median of 12d. GM/Mn/AMn became positive in 
the time window during which empirical antifungaL 
therapy is recommended (2.5 d after fever onset). 
Conclusions: In neutropenic cancer patients, se- 
quential monitoring of GMn/Mn/AMn may con- 
tribute, in combination with other diagnostic tests, 
to identify persistently febrile neutropenic patients 
who do not need empirical antifungaL Rx. 
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Beta-l,3-D-Glucan (BGL) Antigenemia in 
Neutropenic Cancer Patients (Pts) with Invasive 
Aspergillosis (IA) and Candidiasis (IC) 
L. Senn*, J.O. Robinson, S. Schmidt, M. Knaup, 
N. Asahi, S. Satomura, S. Matsuura, B. Duvoisin, 
T. CaLandra, O. Marchetti. Infectious Diseases 
Service, CHUV, Lausanne, Switzerland 
Background: IA and IC are associated with high 
morbidity and mortality in neutropenic cancer pts. 
New diagnostic tests are needed for early diagnosis 
of invasive mycosis. BGL, a fungaL ceLL waLL antigen, 
can be detected in the systemic circulation of 
pts with IA or IC. 
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Objectives: To eval,uate the util,ity of BGL monitor- 
ing in neutropenic cancer pts at high risk of IA and 
IC. 
Methods: Prospective study of consecutive episodes 
of neutropenia (median duration 22 d) in pts with 
acute l,eukemia. IA and IC were defined accord- 
ing to EORTC-MSG criteria. Bl,ood was col,l,ected 
2 times weekl,y before onset of fever and dail,y 
thereafter. BGL was measured by turbidimetric 
or col,orimetric assays (Wako, Japan). Positive 
tests defined by 2 consecutive BGL val,ues >6 and 
>5 pg/ml,, or >11 pg/ml, for both tests (2 cut-off 
val,ues). 
Results: 23 episodes of invasive mycoses oc- 
curred during 130 neutropenic episodes: 12 IC 
(1 proven, 11 probabl,e) and 11 IA (3 proven, 
8 probabl,e). 16 sampl,es/episode (3-35) were an- 
al,yzed over 35 days (17-122). Diagnostic per- 
formance of BGL (turbidimetric test): sensitivity, 
specificity, PPV, NPV, negative l,ikel,ihood ratio were 
43/100/100/86/0.57% and 24/100/100/82/0.76% 
for 2 consecutive val,ues >6 and >11, respec- 
tivel,y. Diagnostic performance of BGL (col,orimet- 
ric test): sensitivity, specificity, PPV, NPV, nega- 
tive l,ikel,ihood ratio were 86/91/72/96/0.15% and 
43/100/100/86/0.57% for 2 consecutive val,ues 
>5 and >11, respectivel,y. Col,orimetric BGL with 
cut-off of 2 consecutives val,ues >5 provided the 
best performance for diagnosis of IA and IC. Me- 
dian time (0d) between fever onset (as first sign 
of IFI) and BGL positivity was significantl,y shorter 
than that between fever onset and conventional. 
diagnosis of IFI (13d) (p < 0.0001). 
Conclusions: Serial. screening of bl,ood beta-l,3-D- 
gl,ucan is a promising non-invasive tool,, in combi- 
nation with other diagnostic methods, to identify 
persistentl,y febril,e neutropenic pts in whom em- 
pirical, therapy may be unnecessary. 
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Invasive Fungal Infections among Pediatric 
Patients with Hematologic Malignancies at 
KFSH&RC/KFCCC&R 
I. Bin-Hussain*, E AI, Kordy, R. Serhan, A. AI, 
Ahmari, A. Bel,gaumi, A. Chaundry, L. Joy, S. AI, 
Jumaah, S. AI, Hajjar, H. Ei,Sol,h. Kin~ Faisal 
Specialist Hospital & Research Center, Riyadh, 
Saudi Arabia 
Objectives: To define the magnitude of the prob- 
l,em, study factors associated with increased risk of 
invasive fungal, infections (IFI) and outcome. 
Methods: From June 1998 to March 2003, al,l, ra- 
diol,ogical, studies of patients with hematol,ogic/ 
oncol,ogic disorders were eval,uated for incl,usion. 
AI,I, cases of invasive fungal, infection were re- 
viewed. The criteria for incl,usion were obvious 
l,esion suggestive of fungal, infection shown on radi- 
ol,ogical, studies, and fungal, infections were cl,assi- 
fled as "proven", "probabl,e', "possibl,e" or "insuf- 
ficient evidence" according to a prior definitions. 
Results: A total, of 1615 patient charts were re- 
viewed. The underl,ying diagnoses incl,ude ALL 410, 
SCT 293, AML 133, non-mal,ignant hematol,- 
ogy 288, NHL/sol,id tumors 491. 152 (9%) had ev- 
idence of fungal, infection (55 [36%] 'definite = 
proven/probabl,e', 97 [64%] 'possibl,e'). Biopsy was 
performed in 94 cases and the findings incl,uded 
budding yeast in 10 patients, septated hyphae 
in 19, and hyphae with no specifications in 12 pa- 
tients. Del,ays in performing diagnostic procedures 
possibl,y resul,ted in the l.ower incidence of 'def- 
inite' IFI (36% vs 64% 'possibl,e"). The overal,l, in- 
cidence of fungal, infection was 9%, being high- 
est for AML (39%), fol,l,owed by ALL (17%). The 
majority of IFI devel,oped during or immediatel,y 
after induction (42% of IFI in AML and 53% of IFI 
in ALL), which can be a target for intervention. 
The infections incl,uded disseminated fungal, infec- 
tion (36%), CDC (11%), pul,monary fungal, infec- 
tion (43%) and asper~illosis (9.5%) incl,uding pul.- 
monary, Para nasal, sinuses, skin and disseminated. 
IFI was radiol,ogical,l,y diagnosed during neutropenia 
in 123 patients (81%). Ten patients died due to 
fungal, infection (7%), 75 (49%) were cured, 26 (17%) 
were al,ive with fungal, infection, and 39 patients 
(26%) died due to primary disease seemingl,y un- 
rel,ated to fungal, infection. Mortal,ity due to IFI 
in this study is l,ess than what is reported in the 
l,iterature and coul,d be a resul,t of our practice 
of earl,y intervention. The average LOS for IFI was 
56 days compared with the usual. 12 days, which 
can add to the increased cost. 
Conclusions: Invasive fungal, infection is becoming 
a serious probl,em. Furthermore, acute invasive 
fungal, infection is associated with a much higher 
mortal,ity. Earl,y diagnosis with prompt antifungal, 
therapy, or even with surgical, intervention, might 
be warranted to save patients' l,ives. 
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Daptomycin Therapy of Gram-Positive Infections 
(GPI) in Pediatric Cancer Patients 
H.L. Hogan*, J.A. Adachi, E.A. Coyl,e, 
K.V.I. Rol,ston. The University o[ Texas, 
M.D. Anderson Cancer Center, Houston, TX, USA 
Background: Daptomycin is a novel, l,ipopep- 
tide recentl,y approved for treatment of compl,i- 
cated skin and skin structure infections (SSTIs) 
